Prophylactic administration of histamine 1 and/or histamine 2 receptor blockers in the prevention of heparin- and protamine-related haemodynamic effects

Basit Öğe Kaydı
dc.authorscopusid6701836292
dc.authorscopusid7005541482
dc.authorscopusid6701408869
dc.authorscopusid57200309617
dc.authorscopusid7003296014
dc.authorscopusid56740746300
dc.contributor.authorKanbak M.
dc.contributor.authorKahraman S.
dc.contributor.authorCelebioglu B.
dc.contributor.authorAkpolat N.
dc.contributor.authorErcan S.
dc.contributor.authorErdem K.
dc.date.accessioned2024-08-04T19:59:22Z
dc.date.available2024-08-04T19:59:22Z
dc.date.issued1996
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe efficacy of prophylactic administration of H1 and H2 receptor blockers to prevent adverse haemodynamic responses to heparin and protamine was studied. The control group (n=10) received no histamine receptor blocker; group HI (n=10) received oral terfenadine 60 mg, group H2 (n=10) received oral ranitidine 300 mg, and group H1+H2 (n=10) received both terfenadine and ranititine on the night before the operation and on call to the operating room. Heparin sulphate 300 U/kg was injected directly into the right atrium, and protamine hydrochloride was administered at the conclusion of bypass over at least three minutes through a peripheral route. Following the injection of heparin, plasma histamine-like activity (H-LA) was increased significantly in all four groups. While systolic, diastolic, mean arterial and central venous pressures were decreased significantly in the control group, no significant changes were observed in the H1 and H2 groups. Protamine infusion did not lead to an increase in H-LA. Prophylactic administration of histamine receptor blockers (H1 or H2) attenuated the heparin-induced adverse haemodynamic response but did not change the protamine-related haemodynamic effects. Factors other than histamine may play a major role in protamine induced cardiovascular changes.en_US
dc.identifier.doi10.1177/0310057x9602400509
dc.identifier.endpage563en_US
dc.identifier.issn0310-057X
dc.identifier.issue5en_US
dc.identifier.pmid8909666en_US
dc.identifier.scopus2-s2.0-0029862772en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage559en_US
dc.identifier.urihttps://doi.org/10.1177/0310057x9602400509
dc.identifier.urihttps://hdl.handle.net/11616/90587
dc.identifier.volume24en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAustralian Society of Anaesthetistsen_US
dc.relation.ispartofAnaesthesia and Intensive Careen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBlood: coagulation, heparin, protamineen_US
dc.subjectHistamine: antagonists, terfenadine, ranitidineen_US
dc.subjectSurgery: cardiovascularen_US
dc.titleProphylactic administration of histamine 1 and/or histamine 2 receptor blockers in the prevention of heparin- and protamine-related haemodynamic effectsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu